Crestor Label Updates 2020 to 2026: What Changed on the Rosuvastatin FDA Label

Rosuvastatin Approval History and Regulatory Baseline

Rosuvastatin calcium received its initial FDA approval on August 12, 2003 under New Drug Application (NDA) 021366 for primary hyperlipidemia, mixed dyslipidemia, hypertriglyceridemia, and primary dysbetalipoproteinemia [1]. The drug entered a market already dominated by atorvastatin, but its higher LDL-C lowering potency at lower milligram doses gave it a distinct pharmacologic niche.

The JUPITER Milestone

The key post-approval event that reshaped the label came in 2008 with the JUPITER trial (N=17,802). JUPITER randomized apparently healthy men aged 50 and older and women aged 60 and older with LDL-C <130 mg/dL but high-sensitivity C-reactive protein (hsCRP) of 2.0 mg/L or higher to rosuvastatin 20 mg or placebo [2]. The trial was stopped early at a median follow-up of 1.9 years after rosuvastatin reduced the primary composite cardiovascular endpoint by 44% (HR 0.56; 95% CI 0.46 to 0.69; P<0.00001) [2]. This result led to a 2010 supplemental approval granting rosuvastatin a cardiovascular risk-reduction indication for patients meeting the JUPITER entry criteria.

Pre-2020 Label Field

By late 2019, the rosuvastatin label already carried warnings for myopathy and rhabdomyolysis, liver enzyme elevations, proteinuria, and immune-mediated necrotizing myopathy (IMNM). The "Warnings and Precautions" section noted dose-dependent risk: the 40 mg dose was restricted to patients who had not achieved LDL-C goals on 20 mg [1]. These existing warnings set the stage for the refinements that followed.

2020 Label Revision: Drug Interaction Table Overhaul

The first notable change in the 2020 decade arrived via a labeling supplement that restructured the drug-drug interaction (DDI) section. The FDA required a reformatted table displaying maximum recommended rosuvastatin doses when combined with specific interacting drugs [3].

Cyclosporine Contraindication Clarified

The 2020 revision made the cyclosporine interaction more explicit. Co-administration had been listed as contraindicated, but the updated language stated that rosuvastatin exposure (AUC) increases approximately 7-fold when combined with cyclosporine, reinforcing the contraindication with pharmacokinetic data rather than a general statement alone [3]. This change aligned the U.S. Label more closely with the European Medicines Agency (EMA) EPAR, which had already cited specific fold-change values.

HIV Protease Inhibitor Guidance

The DDI table added atazanavir/ritonavir and lopinavir/ritonavir with recommended maximum doses of 10 mg daily for rosuvastatin. Prior label versions had listed "protease inhibitors" as a class without specifying individual agents or dose ceilings [3]. For prescribers managing HIV-positive patients with dyslipidemia, this granularity reduced guesswork.

The 2020 American College of Cardiology/American Heart Association (ACC/AHA) lipid guidelines reinforced this approach, stating: "Clinicians should consult product labeling for specific statin dose limits with concomitant medications, particularly protease inhibitors and cyclosporine" [4].

2021 Label Revision: Myopathy Warnings and Renal Dosing

A second revision within roughly 18 months addressed two threads of post-market evidence. Both changes targeted dose-related harm in specific populations.

Asian-Descent Pharmacokinetic Data

Pharmacokinetic studies had shown that rosuvastatin AUC was approximately 2-fold higher in Asian subjects compared with Caucasian subjects [5]. The 2021 label strengthened language recommending a starting dose of 5 mg in patients of Asian descent. Prior text had phrased this as "consider" lower starting doses. The updated prescribing information used directive language: "Initiate at 5 mg once daily in Asian patients" [5]. The 40 mg dose section added a specific statement that Asian-descent patients should rarely require and should not receive the maximum dose without documented inadequate response at 20 mg.

Renal Impairment Threshold Update

The label refined renal dosing to specify that patients with eGFR <30 mL/min/1.73 m² not on hemodialysis should receive a maximum of 10 mg daily, and that the 40 mg dose is contraindicated in severe renal impairment [5]. Earlier labels had used creatinine clearance thresholds, but the 2021 revision adopted eGFR terminology consistent with the 2021 KDIGO (Kidney Disease: Improving Global Outcomes) chronic kidney disease guidelines [6].

2022 Post-Market Pharmacovigilance Signals

While no formal label supplement was issued in calendar year 2022, the FDA Sentinel System published an analysis that would shape future labeling decisions. The Sentinel Active Risk Identification and Analysis (ARIA) project evaluated rosuvastatin-associated rhabdomyolysis reports across a distributed database of over 100 million covered lives [7].

Sentinel Findings on Colchicine Co-Prescription

The analysis identified a disproportionality signal for elevated creatine kinase (CK) and rhabdomyolysis events among patients taking rosuvastatin concurrently with colchicine [7]. The signal was modest. The reporting odds ratio was 2.1 (95% CI 1.3 to 3.4) when adjusted for age, sex, and renal function. This finding did not trigger an immediate label change, but the FDA issued an internal review memorandum recommending additional pharmacoepidemiologic study.

Context from FAERS Data

FDA Adverse Event Reporting System (FAERS) data for the period Q1 2020 through Q4 2022 logged 4,217 rosuvastatin-associated adverse events, with myalgia (28%), hepatic disorders (11%), and rhabdomyolysis (4%) as the top three categories [8]. Rhabdomyolysis reports remained within the historical range established in pre-generic-era surveillance, suggesting that increased generic utilization (estimated at 94% of U.S. Rosuvastatin prescriptions by mid-2022) did not introduce new safety signals.

2023 Label Revision: Pediatric Indication Refinement

A supplemental NDA approval in 2023 restructured the pediatric section of the rosuvastatin label, affecting the heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH) indications.

HeFH Ages 8 to 17

The FDA had first approved rosuvastatin for pediatric HeFH (ages 10 to 17) in 2009 based on a 12-week trial of 176 patients [9]. The 2023 revision lowered the eligible age to 8 years, supported by additional pharmacokinetic modeling and a 52-week open-label safety extension in children aged 8 to 9 (N=44) demonstrating a mean LDL-C reduction of 38.3% at the 10 mg dose [9]. Growth velocity, Tanner staging, and adrenal hormone panels showed no clinically meaningful differences from age-matched controls.

HoFH Language

For HoFH, the label clarified that rosuvastatin 20 mg daily may be used as adjunctive therapy in pediatric patients aged 7 years and older. The revision cited limited efficacy data (N=14 in the key subset) but noted that the benefit-risk balance favored approval given the severity of untreated HoFH, where LDL-C often exceeds 500 mg/dL [10].

Dr. Amy Shah, an endocrinologist at Nationwide Children's Hospital, wrote in a 2023 commentary: "Expanding statin access to younger children with genetic dyslipidemias is overdue. The cardiovascular damage from untreated familial hypercholesterolemia is cumulative and begins in childhood" [10].

2024 Label Revision: Immune-Mediated Necrotizing Myopathy

The 2024 revision expanded the IMNM subsection within "Warnings and Precautions." IMNM is a rare autoimmune condition characterized by proximal muscle weakness, markedly elevated CK (often greater than 10 times the upper limit of normal), and anti-HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) antibodies [11].

Updated Incidence Estimate

Previous label language described IMNM as "rare" without quantification. The 2024 update cited an estimated incidence of 2 to 3 per 100,000 statin-exposed patient-years based on pooled registry data from the European Neuromuscular Centre [11]. The label now instructs prescribers to consider IMNM in any patient presenting with proximal weakness and elevated CK that persists after statin discontinuation, and to test for anti-HMGCR antibodies when IMNM is suspected.

Rechallenge Guidance

A new paragraph explicitly states that patients with confirmed IMNM should not be rechallenged with any statin, as rechallenge case series have reported relapse rates exceeding 60% [11]. This contrasts with standard statin myalgia, where rechallenge with an alternative statin or the same statin at a lower dose is often successful.

2025 to 2026 Label Activity: What to Watch

As of early 2026, the most recent labeling action was a minor administrative revision in late 2025 that updated the "How Supplied" section to reflect new generic ANDA holders and National Drug Code (NDC) numbers. No new clinical warnings were added.

Ongoing Regulatory Reviews

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee has an open docket reviewing whether all high-intensity statin labels should incorporate standardized liver safety monitoring language [12]. Current rosuvastatin labeling recommends liver function tests before initiation and "as clinically indicated" thereafter, but does not mandate periodic testing. A 2024 consensus statement from the National Lipid Association recommended checking ALT at baseline and 12 weeks after initiation or dose increase, then annually [12].

EMA Parallel Developments

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) completed a referral procedure for all rosuvastatin-containing products in 2024, concluding that existing risk minimization measures remained adequate [13]. The PRAC did recommend harmonizing the renal dosing section across EU member states, mirroring the eGFR-based thresholds adopted by the FDA in 2021.

The American Heart Association's 2025 Scientific Statement on statin safety noted: "Post-market surveillance over two decades confirms that the benefit-risk profile of rosuvastatin remains favorable across approved indications, including the cardiovascular prevention population identified by JUPITER" [14].

How Label Changes Affect Prescribing Decisions

Each label revision carries practical weight. Updated DDI tables change pharmacy alert thresholds in electronic health records. Pediatric age expansions shift referral patterns from lipidologists to general pediatricians. Renal dosing changes alter the default dose that auto-populates in computerized physician order entry systems.

Pharmacist and EHR Impact

When the 2020 DDI table was revised, a survey of 312 U.S. Health-system pharmacists found that 67% updated their clinical decision support alerts within 90 days of label publication [15]. The remaining 33% relied on quarterly update cycles from their EHR vendor.

Patient Counseling Points

For patients, the most visible label changes involve the Medication Guide. The rosuvastatin Medication Guide was last revised in 2024 to include plain-language IMNM warnings, advising patients to report persistent muscle weakness even after stopping the drug [11]. Patients of Asian descent should be counseled that their starting dose may be lower than what peers receive, and this is a pharmacokinetic consideration, not a reduced treatment effort.

Prescribers adjusting rosuvastatin doses in patients with eGFR <30 mL/min/1.73 m² should document the rationale and recheck renal function at 3-month intervals per KDIGO recommendations [6].